GM Life M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, resulting in improved blood glucose regulation in patients inadequately controlled by diet, exercise, and monotherapy. GM Life M2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and physical activity. The extended-release formulation allows for sustained plasma drug levels, promoting better adherence and minimizing gastrointestinal side effects commonly associated with Metformin. Patients should be monitored regularly for glycemic control, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, or gastrointestinal disturbances. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components. This medication should be used under medical supervision with appropriate dose adjustments based on therapeutic response and tolerability.